Literature DB >> 9044149

Efficacy of the transthoracic modified Heller myotomy in children with achalasia--a 21-year experience.

J L Lelli1, R A Drongowski, A G Coran.   

Abstract

From 1974 to 1995, 19 children with achalasia of the esophagus have been treated at our institution. Presenting symptoms included vomiting (n = 14), dysphagia (n = 13), failure to thrive (n = 6), and odynophagia (n = 1). Diagnosis was established by a barium swallow in 19, with eight also undergoing esophageal manometry. Six boys and 13 girls with an average age of 10 years (range, 1.3 to 17.6) underwent a transthoracic, modified anterior Heller esophagomyotomy (HM). Five underwent a concomitant, modified, Belsey fundoplication (BF). Follow-up ranging from 6 months to 21 years (mean, 9 years) was accomplished in all 19 patients by both office visits and telephone interviews. Early postoperative follow-up showed initial swallowing difficulty in two (14%) patients with a HM alone and in four out of five (80%) patients treated with a HM and BF. All patients (n = 5) with a HM and BF and one with a HM alone required one esophageal dilation during the first postoperative year. These initial swallowing difficulties resolved in all six patients during this first postoperative year. Late postoperative follow-up, however, indicates occasional, mild dysphagia in two out of five with an HM and BF resulting in complete relief of presenting symptoms in 17 of the 19 patients (90%). All patients rated their overall result as either excellent (68%) or good (32%) with none rating it as fair or poor. None of the 19 patients had clinical evidence of gastroesophageal reflux, although five patients had evidence of nonpathologic reflux noted during upper gastrointestinal x-ray. Recurrent vomiting, asthma, wheezing, or esophagitis symptoms have not been reported by any patients. No patients required reoperation, and there were no deaths or postoperative complications. Modified Heller esophagomyotomy is safe (0% mortality) and effective (90% relief of symptoms) in children with achalasia. A concurrent modified Belsey fundoplication results in early and late mild postoperative dysphagia that was responsive to esophageal dilation. The transthoracic, modified Heller esophagomyotomy without a fundoplication is currently our treatment of choice for achalasia in children.

Entities:  

Mesh:

Year:  1997        PMID: 9044149     DOI: 10.1016/s0022-3468(97)90206-2

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  6 in total

1.  Outcomes of treatment of childhood achalasia.

Authors:  Constance W Lee; David W Kays; Mike K Chen; Saleem Islam
Journal:  J Pediatr Surg       Date:  2010-06       Impact factor: 2.545

2.  A review of achalasia in 33 children.

Authors:  Sunny Zaheed Hussain; Ronald Thomas; Vasundhara Tolia
Journal:  Dig Dis Sci       Date:  2002-11       Impact factor: 3.199

Review 3.  Childhood achalasia: A comprehensive review of disease, diagnosis and therapeutic management.

Authors:  Ashanti L Franklin; Mikael Petrosyan; Timothy D Kane
Journal:  World J Gastrointest Endosc       Date:  2014-04-16

4.  Diagnosis, misdiagnosis, and associated diseases of achalasia in children and adolescents: a twelve-year single center experience.

Authors:  Cristiane Hallal; Carlos O Kieling; Daltro L Nunes; Cristina T Ferreira; Guilherme Peterson; Sérgio G S Barros; Cristina A Arruda; José C Fraga; Helena A S Goldani
Journal:  Pediatr Surg Int       Date:  2012-11-08       Impact factor: 1.827

Review 5.  Laparoscopic esophagomyotomy for achalasia in children: A review.

Authors:  T Kumar Pandian; Nimesh D Naik; Aodhnait S Fahy; Arman Arghami; David R Farley; Michael B Ishitani; Christopher R Moir
Journal:  World J Gastrointest Endosc       Date:  2016-01-25

6.  Obstructive bronchitis and recurrent pneumonia in esophageal achalasia in a child: A CARE compliant case report.

Authors:  Alexandr Evgen'evich Mashkov; Dmitrii Anatolèvich Pykchteev; Alexandr Viktorovic Sigachev; Andrei Viktorovich Bobylev; Johannes Michael Mayr
Journal:  Medicine (Baltimore)       Date:  2018-06       Impact factor: 1.889

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.